COG Clinical Trial Summaries
Acute Lymphoblastic Leukemia (ALL)
- AALL0932: A Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
- AALL1131: A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine in the Very High Risk Stratum
- AALL1231: A Phase 3 Randomized Trial Investigating Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
- AALL1331: Risk-Stratified Randomized Phase 3 Testing of Blinatumomab in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
- AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk (HR) Cytokine Receptor-Like Factor 2-Rearranged (CRLF2-R) and/or Janus Kinase (JAK) Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)
- AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
- AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
- AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones Introduction
- AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Acute Myelogenous Leukemia (AML) studies
- AAML1331: A Phase 3 Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid
- AAML1421: A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML); A Study of CPX-351 Alone Followed by Fludarabine, Cytarabine and G-CSF for Children with Acute Myeloid Leukemia (AML) That Has Come Back
- AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Brain and Spinal Cord Tumor (CNS) studies
- ACNS0332: A Phase 3 Study for Patients with High-risk Medulloblastoma and/or PNET
- ACNS0831: A Phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
- ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
- ACNS1721: A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Children with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Tumor Mutations
- ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Cancer Control and Supportive Care (CCLSC) studies
- ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
- ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
- ACCL1333: A Phase 3 Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (T or B cell) Treated with Pegylated Asparaginase
Ewing Sarcoma studies
- AEWS1031: A Phase 3 Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
- AEWS1221: Randomized Phase 2 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multi-agent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Germ Cell Tumor studies
Hepatoblastoma
Lymphoma - Hodgkin and Non-Hodgkin studies
- AHOD1331: A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
- ANHL1522: A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
- ANHL12P1: A Randomized Phase 2 Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
Neuroblastoma
- ALTE15N2: Late Effects After High-Risk Neuroblastoma (LEAHRN) Study
- ANBL1232: Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
- ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Thera[y for Children with Newly Diagnosed High-Risk Neuroblastoma
Renal (Kidney) Tumors studies
Retinoblastoma studies
Rhabdomyosarcoma and Soft Tissue Tumors studies
- ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas: A Phase 2/3 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
- ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Survivorship and Outcomes studies
- ALTE03N1: Key Adverse Events After Childhood Cancer
- ALTE05N1: Umbrella Long-Term Follow-Up Protocol
- ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
- ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
- ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
- ALTE15N2: Late Effects After High-Risk Neuroblastoma (LEAHRN) Study
- ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
- ALTE16C1: Effects of chemotherapy on fertility in male survivors of osteosarcoma
- ALTE1631 A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
Studies No Longer Open to Patient Entry
Acute Myelogenous Leukemia (AML) studies
Brain and Spinal Cord Tumors (CNS) studies
- ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase 3 Double Randomized Trial
- ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation
- ACNS0334: Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months old
- ACNS0821: A Randomized Phase 2 study for children with recurrent/refractory Medulloblastoma/CNS PNET
- ACNS0822: A Randomized Phase 2/3 Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
- ACNS0927: A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
- ACNS1022: A Phase 2 Randomized Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
- ACNS1123: A Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
- ACNS1221: A Phase 2 Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Cancer Control and Supportive Care (CCLSC) studies
- ACCL0431: A Randomized Phase 3 Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children
- ACCL05C1: A Group-wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
- ACCL0731: Glutamic Acid to Decrease Vincristine Toxicity in Children with Cancer
- ACCL0922: A Phase 2 Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
- ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
- ACCL0934: A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- ACCL1031: Phase 3 Study for patients undergoing myeloablative autologous or allogeneic Hematopoietic Stem Cell Transplantation.
- ACCL1032: A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Cisplatin
- ACCL1034: Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLA-BSI) and Acquisition of Multi-Drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
- ACCL1131: A Phase 3 Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
- ANUR1131: Music Video for AYA - Parent Communication and Resilience
Ewing Sarcoma studies
Lymphoma: Hodgkin and Non-Hodgkin Studies
- AHOD1221: A Phase 1/2 Study of Brentuximab Vedotin In Combination With Gemcitabine For Pediatric And Young Adult Patients With Relapsed Or Refractory Hodgkin Lymphoma
- ANHL1131: Intergroup Trial for Children or Adolescents with B-cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Neuroblastoma
- ANBL09P1: A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
- ANBL1221: A Phase 2 Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Chimeric 14.18 Antibody (ch14.18) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Osteosarcoma
- AOST1321: Phase 2 Study of Denosumab, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
- AOST1322: A Phase 2 Study of Eribulin in Recurrent or Refractory Osteosarcoma
- AOST1421: A Phase 2 Study of Human-Mouse Chimeric Anti-Disaloganglioside Monoclonal Antibody ch14.18 in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
- AOST1521: A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin), in Recurrent or Refractory Osteosarcoma
Rare Tumors studies
- ARAR0331: Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
- ARAR0332: Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy
